BRAF and melanoma: While the use of two kinase inhibitors may constitute a limitation due to increased toxicities, examples such as the use of cobimetinib in combination with vemurafenib in BRAF‐V600‐mutated melanoma,67, 68 sustain the clinical feasibility of such approach.